Literature DB >> 2434207

Flow cytometry and Feulgen cytophotometry in evaluation of effusions.

J Schneller, E Eppich, E Greenebaum, F Elequin, A Sherman, R Wersto, L G Koss.   

Abstract

Fifty-eight effusions (42 pleural and 16 ascitic fluids) from patients with and without cancer were analyzed by conventional cytology and the results compared with DNA patterns generated by flow cytometry of 10(4) nuclei and several modes of Feulgen cytophotometry. In 31 patients (24 without evidence of cancer and seven with history of cancer and cytologically negative fluids), the fluids were diploid by flow cytometry. One fluid with atypical cells from a lymphoma suspect was also diploid. Flow cytometry of 26 cytologically cancerous fluids disclosed aneuploid DNA patterns in 16 and diploid patterns in ten. Feulgen cytophotometry of 11 of these fluids (three aneuploid, eight diploid) was performed on nuclear preparations identical to those used in flow cytometry and on restrained smears used for visual analysis. The analysis was performed in two modes: as a study of 500 sequential nuclei in an automated system, mimicking flow cytometry, and visually selected large, presumably malignant nuclei. In nine of the 11 cases, the DNA content of visually selected cancer cells was aneuploid, even though this DNA pattern was not evident in the analysis of 500 sequential cells. In two cases, both diploid by flow cytometry, the Feulgen analysis confirmed the presence of cancer cells in the diploid range. In samples of 10(4) nuclei representing a mixed population of cells occurring in effusions, the presence of aneuploid cancer cells may not be disclosed by conventional flow cytometry. A larger sample of cells, a detailed analysis of DNA histograms, and perhaps sorting of select cells in the hypertetraploid range, may prove essential before flow cytometry can be accepted as a diagnostic tool in the laboratory in the assessment of effusions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434207     DOI: 10.1002/1097-0142(19870401)59:7<1307::aid-cncr2820590713>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings.

Authors:  B Risberg; B Davidson; H P Dong; J M Nesland; A Berner
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

Review 2.  The study of endocrine tumors by flow and image cytometry.

Authors:  Ingrid Zbieranowski; David Murray
Journal:  Endocr Pathol       Date:  1992-06       Impact factor: 3.943

3.  Flow cytometric analysis of pulmonary fluids and cells for the detection of malignancies.

Authors:  J E Fuhr; A A Kattine; T A Sullivan; H S Nelson
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

4.  Diagnostic value of DNA image cytometry in ulcerative colitis.

Authors:  R Keller; E C Foerster; A Köhler; B Floer; G Winde; H J Terpe; W Domschke
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

5.  Comparison of flow and static image cytometry in the determination of ploidy.

Authors:  D Lanigan; P A McLean; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1993-02       Impact factor: 3.411

6.  Comparison of nucleolar organiser regions and DNA flow cytometry in the evaluation of pleural effusion.

Authors:  M S Huang; M S Tsai; J J Hwang; T H Wang
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

Review 7.  Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review.

Authors:  S K Mohanty; P Dey
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

8.  Value of DNA analysis in addition to cytological testing in the diagnosis of malignant pleural effusions.

Authors:  F Rodríguez de Castro; T Molero; O Acosta; G Julià-Serdà; J Caminero; P Cabrera; T Carrillo
Journal:  Thorax       Date:  1994-07       Impact factor: 9.139

9.  Value of automatic DNA image cytometry for diagnosing lung cancer.

Authors:  Anqi Shi; Wang Min; Lai Xiang; Wu Xu; Tao Jiang
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.